Related references
Note: Only part of the references are listed.Improved production of cytotoxic thailanstatins A and D through metabolic engineering of Burkholderia thailandensis MSMB43 and pilot scale fermentation
Xiangyang Liu et al.
SYNTHETIC AND SYSTEMS BIOTECHNOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Yoshiaki Yamamoto et al.
CLINICAL CANCER RESEARCH (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3′ splice-site organization and activity of U2AF-related proteins
Jana Kralovicova et al.
NUCLEIC ACIDS RESEARCH (2015)
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
Andrew K. Kwegyir-Afful et al.
ONCOTARGET (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
K-H Chang et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Mechanisms for U2AF to define 3′ splice sites and regulate alternative splicing in the human genome
Changwei Shao et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of the androgen receptor splicing in prostate cancer cells
L. L. Liu et al.
ONCOGENE (2014)
Molecular pathways and targets in prostate cancer
Emma Shtivelman et al.
ONCOTARGET (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
mRNA Splicing Variants: Exploiting Modularity to Outwit Cancer Therapy
Scott M. Dehm
CANCER RESEARCH (2013)
Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A. L. M. Eskens et al.
CLINICAL CANCER RESEARCH (2013)
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Lucas J. Brand et al.
CURRENT DRUG TARGETS (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Genomics-Guided Discovery of Thailanstatins A, B, and C As Pre-mRNA Splicing Inhibitors and Antiproliferative Agents from Burkholderia thailandensis MSMB43
Xiangyang Liu et al.
JOURNAL OF NATURAL PRODUCTS (2013)
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
Michael D. Nyquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer
Preethi Ravindranathan et al.
NATURE COMMUNICATIONS (2013)
Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases
James Dominic Mills et al.
NEUROBIOLOGY OF AGING (2012)
ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
Shinichi Yamashita et al.
NEOPLASIA (2012)
Alternatively spliced androgen receptor variants
Scott M. Dehm et al.
ENDOCRINE-RELATED CANCER (2011)
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Kai-Hsiung Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
Charles J. David et al.
GENES & DEVELOPMENT (2010)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Targeting the androgen receptor pathway in prostate cancer
Yu Chen et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing
Qun Pan et al.
NATURE GENETICS (2008)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Daisuke Kaida et al.
NATURE CHEMICAL BIOLOGY (2007)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
Share Paper
